Clinical Trial Update: NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19) [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update for NexCAR19 (Talikabtagene autoleucel), a CAR-T therapy studied in relapsed/refractory B-cell malignancies; the Phase 2/Phase 3 trial is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• High-grade B-cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• NexCAR19 (Talikabtagene autoleucel) (Talikabtagene autoleucel)

Snippet

Sponsor: Health Institutes of Turkey | Conditions: Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL), Relapsed/Refractory Non-Hodgkin Lymphoma | Phase 2, Phase 3 | Status: RECRUITING